Search Results - "Pallavi, S."

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond by Pai‐Scherf, Lee, Blumenthal, Gideon M., Li, Hongshan, Subramaniam, Sriram, Mishra‐Kalyani, Pallavi S., He, Kun, Zhao, Hong, Yu, Jingyu, Paciga, Mark, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard

“…On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of…”
Get full text

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC by Nakajima, Erica C, Drezner, Nicole, Li, Xiaoxue, Mishra-Kalyani, Pallavi S, Liu, Yajun, Zhao, Hong, Bi, Youwei, Liu, Jiang, Rahman, Atiqur, Wearne, Emily, Ojofeitimi, Idara, Hotaki, Lauren Tesh, Spillman, Dianne, Pazdur, Richard, Beaver, Julia A, Singh, Harpreet

“…On May 28, 2021, the FDA granted accelerated approval to sotorasib (Lumakras, Amgen) for the treatment of adults with advanced non-small cell lung cancer…”
Get full text

A new numerical method to solve fractional differential equations in terms of Caputo-Fabrizio derivatives by Mahatekar, Yogita, Scindia, Pallavi S, Kumar, Pushpendra

“…Abstract In this article, we derive a new numerical method to solve fractional differential equations containing Caputo-Fabrizio derivatives. The fundamental…”
Get full text

Extended dissipative synchronization for discrete complex dynamical networks with random successive coupling delays through PID control by Pallavi, S., Sakthivel, N.

“…This work investigates the synchronization problem for a kind of discrete complex dynamical networks (CDNs) including nonlinearities, exogenous disturbance,…”
Get full text

Green synthesis of Silver nanoparticles using Streptomyces hirsutus strain SNPGA-8 and their characterization, antimicrobial activity, and anticancer activity against human lung carcinoma cell line A549 by S.S., Pallavi, Rudayni, Hassan Ahmed, Bepari, Asmatanzeem, Niazi, Shaik Kalimulla, Nayaka, Sreenivasa

“…The current study described the systematic and detailed extracellular synthesis method of silver nanoparticles (AgNPs) using Streptomyces hirsutus strain…”
Get full text

Notch and Wnt Signals Cooperatively Control Cell Proliferation and Tumorigenesis in the Intestine by Fre, Silvia, Pallavi, S. K., Huyghe, Mathilde, Laé, Marick, Janssen, Klaus-Peter, Robine, Sylvie, Artavanis-Tsakonas, Spyros, Louvard, Daniel, Sabatini, David D.

“…Notch and Wnt signals play essential roles in intestinal development dnd homeostasis, yet how they integrate their action to affect intestinal morphogenesis is…”
Get full text

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions by Kim, Janice, Bradford, Diana, Larkins, Erin, Pai-Scherf, Lee H, Chatterjee, Somak, Mishra-Kalyani, Pallavi S, Wearne, Emily, Helms, Whitney S, Ayyoub, Amal, Bi, Youwei, Sun, Jielin, Charlab, Rosane, Liu, Jiang, Zhao, Hong, Liang, Dun, Ghosh, Soma, Philip, Reena, Pazdur, Richard, Theoret, Marc R, Beaver, Julia A, Singh, Harpreet

“…The FDA granted accelerated approval for pralsetinib on September 4, 2020 for non-small cell lung cancer (NSCLC) and December 1, 2020 for thyroid cancer, for:…”
Get full text

FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations by Mathieu, Luckson N, Larkins, Erin, Akinboro, Oladimeji, Roy, Pourab, Amatya, Anup K, Fiero, Mallorie H, Mishra-Kalyani, Pallavi S, Helms, Whitney S, Myers, Claire E, Skinner, Amy M, Aungst, Stephanie, Jin, Runyan, Zhao, Hong, Xia, Huiming, Zirkelbach, Jeanne Fourie, Bi, Youwei, Li, Yangbing, Liu, Jiang, Grimstein, Manuela, Zhang, Xinyuan, Woods, Stacie, Reece, Kelie, Abukhdeir, Abdelrahmman M, Ghosh, Soma, Philip, Reena, Tang, Shenghui, Goldberg, Kirsten B, Pazdur, Richard, Beaver, Julia A, Singh, Harpreet

“…The FDA approved capmatinib and tepotinib on May 6, 2020, and February 3, 2021, respectively. Capmatinib is indicated for patients with metastatic non-small…”
Get full text

Microbial responses on upwelling signature across reversal wind pattern in tropical coastal environment off Mumbai, India by Fulke, Abhay B., Salgaonkar, Pallavi S., Swain, Gopal Krushna, Khade, Komal, Dora, G. Udhaba

“…Upwelling promotes marine productivity through water column mixing. The process disturbs the ecosystem, causing oxygen depletion and thermal variability. This…”
Get full text

Improved trilateration for indoor localization: Neural network and centroid-based approach by Jondhale, Satish R, Jondhale, Amruta S, Deshpande, Pallavi S, Lloret, Jaime

“…Location awareness is the key to success to many location-based services applications such as indoor navigation, elderly tracking, emergency management, and so…”
Get full text

Determination of chlorantraniliprole 18.5% SC in the paddy ecosystem and its risk assessment by Mahato, Saraswati, Naik, R. Harischandra, Bheemanna, M., Pallavi, M. S., Hurali, Sujay, Rao, Saroja Narsing, Naik, M. Nagaraj, Paramsivam, M.

“…Chlorantraniliprole belongsto theanthranilic diamide group is widely used against broad range of lepidopteron pests in a variety of vegetable and rice pests…”
Get full text

The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non‐Small Cell Lung Cancer Treated With a PD‐1/PD‐L1 Blocking Antibody Using Real‐World and Trial Data by Liu, Qi, Mathur, Raina, Xu, Yuan, Torres, Aracelis Z., Miksad, Rebecca A., Liu, Chao, Smithson, Haixia, Wang, Yaning, Zhu, Hao, Booth, Brian, Huang, Shiew‐Mei, Zhi, Jizu, Sridhara, Rajeshwari, Blumenthal, Gideon Michael, Larkins, Erin, Mishra‐Kalyani, Pallavi S., Rivera, Donna R., Kluetz, Paul G., Sharon, Elad

“…Clinical trials have demonstrated the benefit of PD‐1/PD‐L1 blocking antibodies for the treatment of patients with advanced non‐small cell lung cancer (NSCLC)…”
Get full text

Analyzing patient‐reported outcome data when completion differs between arms in open‐label trials: an application of principal stratification by Roydhouse, Jessica K., Gutman, Roee, Bhatnagar, Vishal, Kluetz, Paul G., Sridhara, Rajeshwari, Mishra‐Kalyani, Pallavi S.

“…Purpose Cancer trials are often open‐label and include patient‐reported outcomes (PROs). Previous work has demonstrated that patients may complete PRO…”
Get full text

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations by Chon, Katie, Larkins, Erin, Chatterjee, Somak, Mishra-Kalyani, Pallavi S, Aungst, Stephanie, Wearne, Emily, Subramaniam, Sriram, Li, Yangbing, Liu, Jiang, Sun, Jielin, Charlab, Rosane, Zhao, Hong, Saritas-Yildirim, Banu, Bikkavilli, Rama Kamesh, Ghosh, Soma, Philip, Reena, Beaver, Julia A, Singh, Harpreet

“…The FDA granted accelerated approval for amivantamab-vmjw (hereafter referred to as amivantamab), a bispecific antibody directed against EGFR and…”
Get full text

FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma by Nakajima, Erica C, Vellanki, Paz J, Larkins, Erin, Chatterjee, Somak, Mishra-Kalyani, Pallavi S, Bi, Youwei, Qosa, Hisham, Liu, Jiang, Zhao, Hong, Biable, Missiratch, Hotaki, Lauren Tesh, Shen, Yuan-Li, Pazdur, Richard, Beaver, Julia A, Singh, Harpreet, Donoghue, Martha

“…On October 2, 2020, FDA approved nivolumab with ipilimumab as first-line treatment for adult patients with unresectable malignant pleural mesothelioma (MPM)…”
Get full text

FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review by Koch, Abigail L, Vellanki, Paz J, Drezner, Nicole, Li, Xiaoxue, Mishra-Kalyani, Pallavi S, Shen, Yuan Li, Xia, Huiming, Li, Yangbing, Liu, Jiang, Zirkelbach, Jeanne Fourie, Palazov, Elitza, Gamarian, Aleksandr, Choo, Qiuyi, Girčys, Arūnas, Rohr, Ulrich-Peter, Fesenko, Nataliya, Spillman, Dianne, Pazdur, Richard, Beaver, Julia A, Singh, Harpreet

“…On December 18, 2020, the FDA approved osimertinib as adjuvant therapy in patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19…”
Get full text

Shear stress and microRNAs for better metastatic cancer management by KrishnaPriya, Siluveru, Nair, Pallavi S., Bhalla, Prerna, Karunagaran, D., Suraishkumar, G. K.

“…Metastasis is the process by which cancer cells move from the primary location to establish themselves in a new location in the human body. It is still a…”
Get full text

Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis by Goulart, Bernardo Haddock Lobo, Mushti, Sirisha L, Chatterjee, Somak, Larkins, Erin, Mishra-Kalyani, Pallavi S, Pazdur, Richard, Kluetz, Paul G, Singh, Harpreet

“…Radiographic changes might not fully capture the treatment effects of immune checkpoint inhibitors (ICIs). We aimed to assess correlations of overall response…”
Get full text

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC by Akinboro, Oladimeji, Larkins, Erin, Pai-Scherf, Lee H, Mathieu, Luckson N, Ren, Yi, Cheng, Joyce, Fiero, Mallorie H, Fu, Wentao, Bi, Youwei, Kalavar, Shyam, Jafri, Samina, Mishra-Kalyani, Pallavi S, Fourie Zirkelbach, Jeanne, Li, Hongshan, Zhao, Hong, He, Kun, Helms, Whitney S, Chuk, Meredith K, Wang, Min, Bulatao, Ilynn, Herz, Jonathan, Osborn, Blaire L, Xu, Yuan, Liu, Jiang, Gong, Yutao, Sickafuse, Sharon, Cohen, Rebecca, Donoghue, Martha, Pazdur, Richard, Beaver, Julia A, Singh, Harpreet

“…FDA's approval of cemiplimab-rwlc on February 22, 2021, follows prior approvals of pembrolizumab and atezolizumab for similar indications as first-line…”
Get full text

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer by Duke, Elizabeth S, Barone, Amy K, Chatterjee, Somak, Mishra-Kalyani, Pallavi S, Shen, Yuan-Li, Isikwei, Emasenyie, Zhao, Hong, Bi, Youwei, Liu, Jiang, Rahman, Nam Atiqur, Wearne, Emily, Leighton, John K, Stephenson, Maritsa, Ojofeitimi, Idara, Scepura, Barbara, Nair, Abhilasha, Pazdur, Richard, Beaver, Julia A, Singh, Harpreet

“…On September 17, 2021, the FDA approved cabozantinib (Cabometyx; Exelixis, Inc.) for the treatment of adult and pediatric patients 12 years of age and older…”
Get full text